Arbutus Biopharma (ABUS) Tops Q2 EPS by 1c

Arbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of ($0.10), $0.01 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $4.65 million versus the consensus estimate of $6.18 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Linde (LIN) PT Lowered to $563 at Bernstein SocGen Group
• GE Vernova (GEV) PT Raised to $1,185 at Jefferies